Loading...
•
Mar 31, 2022
BioNano Q1 2022 Earnings Report
Reported 80% year-over-year revenue growth and achieved all Q1 2022 ELEVATE! milestones.
Key Takeaways
Bionano Genomics reported strong Q1 2022 results, with a record revenue of $5.7 million, representing 80% year-over-year growth. The company expanded its Saphyr system installed base and launched the Rare Undiagnosed Genetic Disease (RUGD) initiative. They ended the quarter with a strong balance sheet, holding $216.5 million in cash, cash equivalents, and available-for-sale securities.
Total revenue for Q1 2022 was $5.7 million, up 80% from Q1 2021.
Expanded the installed base of Saphyr systems to 176 as of the end of Q1 2022, up 64% over Q1 2021.
Sold 3,225 nanochannel array flowcells during Q1 2022, a 24% growth over Q1 2021.
At March 31, 2022, the Company had cash, cash equivalents, and available-for-sale securities of $216.5 million.
Revenue by Segment
Forward Guidance
Bionano Genomics remains on track to achieve its revenue guidance in the range of $24 million to $27 million for the year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...